{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:21:20Z","timestamp":1788934880773,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873112"],"award-info":[{"award-number":["81873112"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2020423009"],"award-info":[{"award-number":["H2020423009"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Talent Project Training Funding Project of Hebei Province","award":["A201902015"],"award-info":[{"award-number":["A201902015"]}]},{"name":"Scientific and technological capability improvement project of Hebei University of Chinese Medicine","award":["KTZ2019002"],"award-info":[{"award-number":["KTZ2019002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nat Med"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s11418-022-01641-2","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T16:05:53Z","timestamp":1662480353000},"page":"28-40","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Dihydroartemisinin inhibited the Warburg effect through YAP1\/SLC2A1 pathway in hepatocellular carcinoma"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2238-8400","authenticated-orcid":false,"given":"Qing","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caige","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"1641_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"1641_CR2","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1586\/17474124.2015.1028363","volume":"9","author":"MC Wallace","year":"2015","unstructured":"Wallace MC, Preen D, Jeffrey GP, Adams LA (2015) The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol 9:765\u2013779. https:\/\/doi.org\/10.1586\/17474124.2015.1028363","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1641_CR3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (New York, NY) 324:1029\u20131033. https:\/\/doi.org\/10.1126\/science.1160809","journal-title":"Science (New York, NY)"},{"key":"1641_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"1641_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.ccr.2008.05.005","volume":"13","author":"G Kroemer","year":"2008","unstructured":"Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer\u2019s Achilles\u2019 heel. Cancer Cell 13:472\u2013482. https:\/\/doi.org\/10.1016\/j.ccr.2008.05.005","journal-title":"Cancer Cell"},{"key":"1641_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.mam.2012.07.001","volume":"34","author":"M Mueckler","year":"2013","unstructured":"Mueckler M, Thorens B (2013) The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med 34:121\u2013138. https:\/\/doi.org\/10.1016\/j.mam.2012.07.001","journal-title":"Mol Aspects Med"},{"key":"1641_CR7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/sla.0000000000001109","volume":"263","author":"JA Goos","year":"2016","unstructured":"Goos JA, de Cuba EM, Coup\u00e9 VM, Diosdado B, Delis-Van Diemen PM, Karga C, Beli\u00ebn JA, der Houven M-V, van Oordt CW, Geldof AA, Meijer GA, Hoekstra OS, Fijneman RJ (2016) Glucose transporter 1 (SLC2A1) and vascular endothelial growth factor A (VEGFA) predict survival after resection of colorectal cancer liver metastasis. Ann Surg 263:138\u2013145. https:\/\/doi.org\/10.1097\/sla.0000000000001109","journal-title":"Ann Surg"},{"key":"1641_CR8","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/cam4.1008","volume":"6","author":"X Ding","year":"2017","unstructured":"Ding X, Liu J, Liu T, Ma Z, Wen D, Zhu J (2017) miR-148b inhibits glycolysis in gastric cancer through targeting SLC2A1. Cancer Med 6:1301\u20131310. https:\/\/doi.org\/10.1002\/cam4.1008","journal-title":"Cancer Med"},{"key":"1641_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168907","volume":"11","author":"HW Sun","year":"2016","unstructured":"Sun HW, Yu XJ, Wu WC, Chen J, Shi M, Zheng L, Xu J (2016) GLUT1 and ASCT2 as predictors for prognosis of hepatocellular carcinoma. PLoS One 11:e0168907. https:\/\/doi.org\/10.1371\/journal.pone.0168907","journal-title":"PLoS One"},{"key":"1641_CR10","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.2353\/ajpath.2009.080596","volume":"174","author":"T Amann","year":"2009","unstructured":"Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, Stoeltzing O, Warnecke C, Sch\u00f6lmerich J, Oefner PJ, Kreutz M, Bosserhoff AK, Hellerbrand C (2009) GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol 174:1544\u20131552. https:\/\/doi.org\/10.2353\/ajpath.2009.080596","journal-title":"Am J Pathol"},{"key":"1641_CR11","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s12253-019-00708-y","volume":"26","author":"Y Lei","year":"2020","unstructured":"Lei Y, Hu Q, Gu J (2020) Expressions of carbohydrate response element binding protein and glucose transporters in liver cancer and clinical significance. Pathol Oncol Res: POR 26:1331\u20131340. https:\/\/doi.org\/10.1007\/s12253-019-00708-y","journal-title":"Pathol Oncol Res: POR"},{"key":"1641_CR12","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.3892\/or.2017.5472","volume":"37","author":"R Shang","year":"2017","unstructured":"Shang R, Pu M, Li Y, Wang D (2017) FOXM1 regulates glycolysis in hepatocellular carcinoma by transactivating glucose transporter 1 expression. Oncol Rep 37:2261\u20132269. https:\/\/doi.org\/10.3892\/or.2017.5472","journal-title":"Oncol Rep"},{"key":"1641_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ceb.2019.07.006","volume":"61","author":"S Zhang","year":"2019","unstructured":"Zhang S, Zhou D (2019) Role of the transcriptional coactivators YAP\/TAZ in liver cancer. Curr Opin Cell Biol 61:64\u201371. https:\/\/doi.org\/10.1016\/j.ceb.2019.07.006","journal-title":"Curr Opin Cell Biol"},{"key":"1641_CR14","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1002\/cncr.24495","volume":"115","author":"MZ Xu","year":"2009","unstructured":"Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM (2009) Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115:4576\u20134585. https:\/\/doi.org\/10.1002\/cncr.24495","journal-title":"Cancer"},{"key":"1641_CR15","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jhep.2015.07.008","volume":"63","author":"D Yimlamai","year":"2015","unstructured":"Yimlamai D, Fowl BH, Camargo FD (2015) Emerging evidence on the role of the Hippo\/YAP pathway in liver physiology and cancer. J Hepatol 63:1491\u20131501. https:\/\/doi.org\/10.1016\/j.jhep.2015.07.008","journal-title":"J Hepatol"},{"key":"1641_CR16","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.cub.2007.10.039","volume":"17","author":"FD Camargo","year":"2007","unstructured":"Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, Brummelkamp TR (2007) YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol: CB 17:2054\u20132060. https:\/\/doi.org\/10.1016\/j.cub.2007.10.039","journal-title":"Curr Biol: CB"},{"key":"1641_CR17","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.celrep.2013.04.020","volume":"3","author":"H Wu","year":"2013","unstructured":"Wu H, Xiao Y, Zhang S, Ji S, Wei L, Fan F, Geng J, Tian J, Sun X, Qin F, Jin C, Lin J, Yin ZY, Zhang T, Luo L, Li Y, Song S, Lin SC, Deng X, Camargo F, Avruch J, Chen L, Zhou D (2013) The Ets transcription factor GABP is a component of the hippo pathway essential for growth and antioxidant defense. Cell Rep 3:1663\u20131677. https:\/\/doi.org\/10.1016\/j.celrep.2013.04.020","journal-title":"Cell Rep"},{"key":"1641_CR18","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1002\/hep.25899","volume":"56","author":"T Zhang","year":"2012","unstructured":"Zhang T, Zhang J, You X, Liu Q, Du Y, Gao Y, Shan C, Kong G, Wang Y, Yang X, Ye L, Zhang X (2012) Hepatitis B virus X protein modulates oncogene yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology (Baltimore, MD) 56:2051\u20132059. https:\/\/doi.org\/10.1002\/hep.25899","journal-title":"Hepatology (Baltimore, MD)"},{"key":"1641_CR19","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/hep.26420","volume":"58","author":"J Wang","year":"2013","unstructured":"Wang J, Ma L, Weng W, Qiao Y, Zhang Y, He J, Wang H, Xiao W, Li L, Chu Q, Pan Q, Yu Y, Sun F (2013) Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer. Hepatology (Baltimore, MD) 58:1011\u20131020. https:\/\/doi.org\/10.1002\/hep.26420","journal-title":"Hepatology (Baltimore, MD)"},{"key":"1641_CR20","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/J.biopha.2017.08.091","volume":"95","author":"C Lin","year":"2017","unstructured":"Lin C, Xu X (2017) YAP1-TEAD1-Glut1 axis dictates the oncogenic phenotypes of breast cancer cells by modulating glycolysis. Biomed Pharmacother = Biomedecine Pharmacotherapie 95:789\u2013794. https:\/\/doi.org\/10.1016\/J.biopha.2017.08.091","journal-title":"Biomed Pharmacother = Biomedecine Pharmacotherapie"},{"key":"1641_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.canlet.2014.09.003","volume":"355","author":"D Zhang","year":"2014","unstructured":"Zhang D, Li J, Wang F, Hu J, Wang S, Sun Y (2014) 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Lett 355:176\u2013183. https:\/\/doi.org\/10.1016\/j.canlet.2014.09.003","journal-title":"Cancer Lett"},{"key":"1641_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1023\/a:1023756707900","volume":"63","author":"S Oudard","year":"2003","unstructured":"Oudard S, Carpentier A, Banu E, Fauchon F, Celerier D, Poupon MF, Dutrillaux B, Andrieu JM, Delattre JY (2003) Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol 63:81\u201386. https:\/\/doi.org\/10.1023\/a:1023756707900","journal-title":"J Neurooncol"},{"key":"1641_CR23","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3892\/ol.2021.12914","volume":"22","author":"L Hao","year":"2021","unstructured":"Hao L, Li S, Peng Q, Guo Y, Ji J, Zhang Z, Xue Y, Liu Y, Shi X (2021) Anti-malarial drug dihydroartemisinin downregulates the expression levels of CDK1 and CCNB1 in liver cancer. Oncol Lett 22:653. https:\/\/doi.org\/10.3892\/ol.2021.12914","journal-title":"Oncol Lett"},{"key":"1641_CR24","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/ptr.6332","volume":"33","author":"X Shi","year":"2019","unstructured":"Shi X, Wang L, Ren L, Li J, Li S, Cui Q, Li S (2019) Dihydroartemisinin, an antimalarial drug, induces absent in melanoma 2 inflammasome activation and autophagy in human hepatocellular carcinoma HepG2215 cells. Phytother Res: PTR 33:1413\u20131425. https:\/\/doi.org\/10.1002\/ptr.6332","journal-title":"Phytother Res: PTR"},{"key":"1641_CR25","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.bcp.2012.02.002","volume":"83","author":"CZ Zhang","year":"2012","unstructured":"Zhang CZ, Zhang H, Yun J, Chen GG, Lai PB (2012) Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem Pharmacol 83:1278\u20131289. https:\/\/doi.org\/10.1016\/j.bcp.2012.02.002","journal-title":"Biochem Pharmacol"},{"key":"1641_CR26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ejphar.2019.04.018","volume":"854","author":"S Li","year":"2019","unstructured":"Li S, Huang P, Gan J, Ling X, Du X, Liao Y, Li L, Meng Y, Li Y, Bai Y (2019) Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2. Eur J Pharmacol 854:232\u2013239. https:\/\/doi.org\/10.1016\/j.ejphar.2019.04.018","journal-title":"Eur J Pharmacol"},{"key":"1641_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120426","volume":"10","author":"YJ Mi","year":"2015","unstructured":"Mi YJ, Geng GJ, Zou ZZ, Gao J, Luo XY, Liu Y, Li N, Li CL, Chen YQ, Yu XY, Jiang J (2015) Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells. PLoS One 10:e0120426. https:\/\/doi.org\/10.1371\/journal.pone.0120426","journal-title":"PLoS One"},{"key":"1641_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"DS Chandrashekar","year":"2017","unstructured":"Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, Varambally S (2017) UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia (New York, NY) 19:649\u2013658. https:\/\/doi.org\/10.1016\/j.neo.2017.05.002","journal-title":"Neoplasia (New York, NY)"},{"key":"1641_CR29","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.181006","volume":"5","author":"O Menyh\u00e1rt","year":"2018","unstructured":"Menyh\u00e1rt O, Nagy \u00c1, Gy\u0151rffy B (2018) Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci 5:181006. https:\/\/doi.org\/10.1098\/rsos.181006","journal-title":"R Soc Open Sci"},{"key":"1641_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan2507","author":"M Uhlen","year":"2017","unstructured":"Uhlen M, Zhang C, Lee S, Sj\u00f6stedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, Sanli K, von Feilitzen K, Oksvold P, Lundberg E, Hober S, Nilsson P, Mattsson J, Schwenk JM, Brunnstr\u00f6m H, Glimelius B, Sj\u00f6blom T, Edqvist PH, Djureinovic D, Micke P, Lindskog C, Mardinoglu A, Ponten F (2017) A pathology atlas of the human cancer transcriptome. Science (New York, NY). https:\/\/doi.org\/10.1126\/science.aan2507","journal-title":"Science (New York, NY)"},{"key":"1641_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11010-020-03861-0","volume":"475","author":"S Li","year":"2020","unstructured":"Li S, Ji J, Zhang Z, Peng Q, Hao L, Guo Y, Zhou W, Cui Q, Shi X (2020) Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1. Mol Cell Biochem 475:79\u201391. https:\/\/doi.org\/10.1007\/s11010-020-03861-0","journal-title":"Mol Cell Biochem"},{"key":"1641_CR32","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.2147\/cmar.S258196","volume":"12","author":"H Tian","year":"2020","unstructured":"Tian H, Zhu X, Lv Y, Jiao Y, Wang G (2020) Glucometabolic reprogramming in the hepatocellular carcinoma microenvironment: cause and effect. Cancer Manag Res 12:5957\u20135974. https:\/\/doi.org\/10.2147\/cmar.S258196","journal-title":"Cancer Manag Res"},{"key":"1641_CR33","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","volume":"17","author":"X Wu","year":"2019","unstructured":"Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L, Liu X (2019) Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J 17:661\u2013674. https:\/\/doi.org\/10.1016\/j.csbj.2019.03.006","journal-title":"Comput Struct Biotechnol J"},{"key":"1641_CR34","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.2147\/dddt.S248872","volume":"14","author":"P Gao","year":"2020","unstructured":"Gao P, Shen S, Li X, Liu D, Meng Y, Liu Y, Zhu Y, Zhang J, Luo P, Gu L (2020) Dihydroartemisinin Inhibits the proliferation of leukemia cells K562 by suppressing PKM2 and GLUT1 mediated aerobic glycolysis. Drug Design Dev Ther 14:2091\u20132100. https:\/\/doi.org\/10.2147\/dddt.S248872","journal-title":"Drug Design Dev Ther"},{"key":"1641_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116730","volume":"233","author":"W Zhu","year":"2019","unstructured":"Zhu W, Li Y, Zhao D, Li H, Zhang W, Xu J, Hou J, Feng X, Wang H (2019) Dihydroartemisinin suppresses glycolysis of LNCaP cells by inhibiting PI3K\/AKT pathway and downregulating HIF-1\u03b1 expression. Life Sci 233:116730. https:\/\/doi.org\/10.1016\/j.lfs.2019.116730","journal-title":"Life Sci"},{"key":"1641_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.fct.2013.02.017","volume":"56","author":"HG Kim","year":"2013","unstructured":"Kim HG, Yang JH, Han EH, Choi JH, Khanal T, Jeong MH, Jeong TC, Jeong HG (2013) Inhibitory effect of dihydroartemisinin against phorbol ester-induced cyclooxygenase-2 expression in macrophages. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc 56:93\u201399. https:\/\/doi.org\/10.1016\/j.fct.2013.02.017","journal-title":"Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc"},{"key":"1641_CR37","doi-asserted-by":"publisher","first-page":"15280","DOI":"10.1038\/ncomms15280","volume":"8","author":"X Zhang","year":"2017","unstructured":"Zhang X, Qiao Y, Wu Q, Chen Y, Zou S, Liu X, Zhu G, Zhao Y, Chen Y, Yu Y, Pan Q, Wang J, Sun F (2017) The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis. Nat Commun 8:15280. https:\/\/doi.org\/10.1038\/ncomms15280","journal-title":"Nat Commun"},{"key":"1641_CR38","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.15252\/embj.201490379","volume":"34","author":"E Enzo","year":"2015","unstructured":"Enzo E, Santinon G, Pocaterra A, Aragona M, Bresolin S, Forcato M, Grifoni D, Pession A, Zanconato F, Guzzo G, Bicciato S, Dupont S (2015) Aerobic glycolysis tunes YAP\/TAZ transcriptional activity. EMBO J 34:1349\u20131370. https:\/\/doi.org\/10.15252\/embj.201490379","journal-title":"EMBO J"},{"key":"1641_CR39","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/ncb3113","volume":"17","author":"W Wang","year":"2015","unstructured":"Wang W, Xiao ZD, Li X, Aziz KE, Gan B, Johnson RL, Chen J (2015) AMPK modulates hippo pathway activity to regulate energy homeostasis. Nat Cell Biol 17:490\u2013499. https:\/\/doi.org\/10.1038\/ncb3113","journal-title":"Nat Cell Biol"},{"key":"1641_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2017.83","volume":"6","author":"Y Gao","year":"2017","unstructured":"Gao Y, Yang Y, Yuan F, Huang J, Xu W, Mao B, Yuan Z, Bi W (2017) TNF\u03b1-YAP\/p65-HK2 axis mediates breast cancer cell migration. Oncogenesis 6:e383. https:\/\/doi.org\/10.1038\/oncsis.2017.83","journal-title":"Oncogenesis"},{"key":"1641_CR41","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1517\/14728220903307509","volume":"13","author":"T Amann","year":"2009","unstructured":"Amann T, Hellerbrand C (2009) GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets 13:1411\u20131427. https:\/\/doi.org\/10.1517\/14728220903307509","journal-title":"Expert Opin Ther Targets"}],"container-title":["Journal of Natural Medicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11418-022-01641-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11418-022-01641-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11418-022-01641-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T00:07:25Z","timestamp":1673136445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11418-022-01641-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1641"],"URL":"https:\/\/doi.org\/10.1007\/s11418-022-01641-2","relation":{},"ISSN":["1340-3443","1861-0293"],"issn-type":[{"value":"1340-3443","type":"print"},{"value":"1861-0293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"assertion":[{"value":"4 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}